Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8648097 | VISIOX PHARMA | Pyridylaminoacetic acid compound |
Oct, 2029
(5 years from now) | |
US10774072 | VISIOX PHARMA | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685986 | VISIOX PHARMA | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(5 years from now) | |
US10179127 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US9415038 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
USRE48183 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US11197849 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US10765750 | VISIOX PHARMA | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US11793798 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US10702511 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US11666563 | VISIOX PHARMA | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
Jul, 2039
(15 years from now) |
Omlonti is owned by Visiox Pharma.
Omlonti contains Omidenepag Isopropyl.
Omlonti has a total of 11 drug patents out of which 0 drug patents have expired.
Omlonti was authorised for market use on 22 September, 2022.
Omlonti is available in solution;ophthalmic dosage forms.
Omlonti can be used as method of treating open-angle glaucoma or ocular hypertension in patients.
Drug patent challenges can be filed against Omlonti from 22 September, 2026.
The generics of Omlonti are possible to be released after 16 July, 2039.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC